Weight Loss Drugs: A Heart and Pancreas Safe Option for High Triglycerides
A groundbreaking study conducted by researchers at Intermountain Health in Salt Lake City has revealed that weight loss drugs, specifically GLP-1 receptor agonists (GLP1RAs), are safe for individuals with high triglycerides, reducing the risk of pancreatitis and adverse cardiac events.
Since their approval in 2005, GLP1RAs have been a subject of caution for clinicians when prescribed to patients with very high triglycerides due to the potential risk of pancreatitis and the drugs' interaction with the pancreas. However, the new study challenges this notion.
The research team analyzed the electronic health records of patients treated at Intermountain Health between 2006 and 2025, focusing on those over 18 years old with Type 2 diabetes and/or a body mass index over 27. A critical aspect of their analysis was the presence of severe hypertriglyceridemia (HTG), defined as a triglyceride level over 500.
Surprisingly, the study found no increased risk of pancreatitis in patients prescribed GLP1RAs, even among those with severe HTG. Moreover, for patients without a history of pancreatitis, GLP1RA medication significantly reduced the risk of developing the condition by four times.
Leslie Iverson, a cardiovascular prevention and research clinician at Intermountain Health, emphasized the severity of pancreatitis and the importance of avoiding its recurrence. The findings, she noted, demonstrate no link between GLP1RAs and pancreatitis in high triglyceride patients, and even suggest a protective effect against the condition.
The study's results were presented at the American Heart Association Scientific Sessions 2025 in New Orleans on November 9. Iverson highlighted that severe HTG should not deter clinicians from prescribing GLP1RA medications to eligible patients, as it enhances treatment options. Additionally, she observed a positive impact on triglyceride levels in patients on GLP1RA medication, attributed to the drugs' ability to address underlying issues like diabetes and obesity.
This research provides valuable insights for healthcare professionals, offering reassurance regarding the safety of weight loss drugs for individuals with high triglycerides and a potential new approach to managing pancreatitis risk.
